Two new types of anticancer medicines are included in the basic package. Minister Bruno Bruins (Medical Care) has made agreements with the manufacturers about the price of the products.
One drug is for the treatment of a specific type of lung cancer, the other for different types of breast cancer. Approximately 2,700 patients benefit from treatment with these drugs.
Durvalumab (for lung cancer patients) and abemaciclib (for breast cancer patients) were not immediately included in the basic package due to the high costs.
The funds would cost more than 50,000 euros per treatment without a price agreement. Where the price now comes out, is not disclosed at the request of the manufacturers.
"Disappointing that price negotiations are needed"
"That patients now have access to these drugs is good news," says Bruins. "At the same time, it remains disappointing that this requires price negotiations and that I cannot make the result of those negotiations public."
It is more common that expensive medicines are not immediately reimbursed by health insurance. The price that the ministry agrees in this type of negotiation is generally not disclosed.
The Ministry will come later this year with a total overview of the savings in 2017 and 2018.
- Want to know what you missed at night? And an update on the most important news around lunch? Subscribe now to our daily newsletter!